Eli Lilly Licenses AlzeCure’s Preclinical Alzheimer’s Candidate
The deal gives Lilly global development rights to ACD680 with a $10 million upfront payment and milestone and royalty terms that could push pre-royalty payouts past $1 billion pending Swedish foreign investment approval.
Overview
- AlzeCure announced the licensing agreement with Eli Lilly on Tuesday, June 9, granting Lilly worldwide development and commercialization rights to ACD680, a preclinical small‑molecule gamma‑secretase modulator.
- AlzeCure will receive $10 million upfront plus development and commercial milestone payments and tiered mid‑single digit royalties, with the company saying total value excluding royalties may exceed $1 billion.
- The announcement triggered a dramatic market response, with AlzeCure shares rising more than 301% on the news.
- ACD680 is designed to lower production of the toxic amyloid‑beta 42 protein and raise shorter, benign amyloid fragments such as Aβ37 and Aβ38 using a small‑molecule gamma‑secretase modulation approach.
- The transaction has not closed and remains subject to customary conditions including Swedish foreign direct investment approval, leaving the asset’s clinical risk with Lilly while giving AlzeCure immediate non‑dilutive capital and third‑party validation.